it is not Yet clear whether Curevac will bring an effective vaccine against the Coronavirus on the market. Still, there is not even data from a clinical trial of the vaccine, which the tübingen-based biotech company with a high-pressure are developed. And yet, only the hope of the society, but now also the investors on the success of the company rests.
not even the German taxpayers, via the Federal last for several weeks. Had to drain, finally, in the competition for future vaccine capacity and for fear of significant technologies could in an IPO on the American Nasdaq stock exchange in the future, slightly, before, with a 300 million Euro is involved. Established in 2000, the biotech company has now used the favor of the hour and dares to take the Gang on the floor.
With a view to the positive development of the share prices of competitors such as Biontech and Moderna, the timing should be well chosen. Now it remains, however, for investors and for society, to hope that Curevacs technologies show success in the biotechnology at all.
